A simulation of loading doses for vancomycin continuous infusion regimens in intensive care

Infectious Diseases
Martin ŠímaOndřej Slanař

Abstract

Delayed achievement of target vancomycin serum concentrations may adversely affect clinical outcomes. The objective of this retrospective study was to compare the prediction accuracy of different body weight descriptors for volume of distribution and to propose an optimal loading dose (LD) for continuous infusion regimens in adults. Pharmacokinetic variables were computed using one-compartmental analysis. Simulated LDs of vancomycin were evaluated for each patient. Volume of distribution, clearance, and half-life median values (interquartile range) for vancomycin in the study population (n = 30) were 0.45 (0.39-0.61) L.kg-1, 0.026 (0.015-0.040) L.h-1.kg-1, and 10.3 (7.7-21.3) h, respectively. The observed volume of distribution was better predicted by total body weight (TBW) than by the ideal body weight or the adjusted body weight. An LD of 10.7 mg per kg TBW was optimal in our study population. Using this LD, 17.9% of simulated vancomycin serum levels were just below the therapeutic range, only 10.7% concentrations exceeded the target range and no concentration was toxic. The use of a LD would lead to reduced median time to reach target concentrations from 17 to 1 h.

References

Apr 1, 1984·Antimicrobial Agents and Chemotherapy·G R MatzkeW F Keane
Jan 1, 1983·European Journal of Clinical Pharmacology·L A BauerD A Simonowitz
Sep 1, 1982·Antimicrobial Agents and Chemotherapy·J C RotschaferL D Solem
Jul 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R WurtzK Rodvold
Feb 7, 2001·The Journal of Antimicrobial Chemotherapy·J T WangS C Chang
May 27, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas P LodiseMichael J Rybak
Jul 17, 2004·British Journal of Clinical Pharmacology·Bruce Green, Stephen B Duffull
Jul 24, 2004·Journal of Clinical Pharmacy and Therapeutics·A VuagnatL Bernard
Feb 14, 2006·International Journal of Antimicrobial Agents·I MohammediD Robert
May 9, 2006·Critical Care Clinics·Bradley A BoucherJoseph M Swanson
Feb 2, 2011·Mayo Clinic Proceedings·Surbhi LeekhaRandall S Edson
Mar 16, 2011·Antimicrobial Agents and Chemotherapy·Jason A RobertsJeffrey Lipman
Mar 31, 2012·Journal of Critical Care·Bernd SaugelWolfgang Huber
Jan 22, 2013·Antimicrobial Agents and Chemotherapy·Natasha E HolmesPaul D R Johnson
Oct 30, 2013·Antimicrobial Agents and Chemotherapy·Michael N NeelyThomas P Lodise
Apr 14, 2015·Journal of Clinical Pharmacy and Therapeutics·M F WaineoD L Brown
Mar 19, 2016·International Journal of Antimicrobial Agents·Abdulaziz S AlobaidJason A Roberts
May 18, 2016·Critical Care : the Official Journal of the Critical Care Forum·Jean-Louis VincentMassimo Antonelli
May 25, 2016·Antimicrobial Agents and Chemotherapy·Stefano CristalliniFabio Silvio Taccone

❮ Previous
Next ❯

Citations

Aug 18, 2017·Infectious Diseases·Yi-Chia SuChih-Chien Wu
Apr 6, 2019·Infectious Diseases·Pavla PokornáOndřej Slanař
Apr 16, 2019·Journal of Chemotherapy·Pavla PokornáOndřej Slanař
Aug 25, 2021·European Journal of Hospital Pharmacy. Science and Practice·Martin ŠímaOndřej Slanař

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.